Posted on December 16, 2017 by Sitemaster
A newly published research letter in JAMA Oncology is entitled “Patient-paired sample congruence between 2 commercial liquid biopsy tests”. The two tests are both said — by the companies that market them — to have high clinical sensitivity and specificity in the identification of specific genetic markers associated with high-risk forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: biopsy, genetic, inconsistency, liquid, medicine, personalized, problem, result, test | 2 Comments »
Posted on October 24, 2017 by Sitemaster
Some people aren’t going to be happy about the following data, but they come from one of the most sophisticated prostate cancer imaging centers in the world … and they make it very clear indeed that multiparametric MRI scanning (mpMRI) is less than perfect in identification of risk for prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: accuracy, false, mpMRI, negative, result, scan | 2 Comments »
Posted on June 16, 2017 by Sitemaster
Barvarian Nordic has again delayed (slightly) when they expect to have the initial results of the Phase III clinical trial of Prostvac in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development | Tagged: mCRPC, outcome, Prostvac, result, trial | Leave a comment »
Posted on September 24, 2016 by Sitemaster
As we have pointed out regularly over the years, all prostate cancers are by no means the same. And a recently published paper in European Urology makes the inherent diversity in the subtypes of prostate cancer even clearer — even within any one specific patient. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: Diagnosis, genetic, genomic, prognosis, result, test, variation | 16 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 